Targeting leukemogenic gene expression via chromatin regulatory complexes

Position

  • 2016 Group Leader and Instructor in Medicine, III. Department of Medicine, University Medical Center, Johannes Gutenberg-University Mainz
  • 2013-2015  Postdoctoral Research Fellow (DFG Scholar), Memorial Sloan Kettering Cancer Center NY, USA
  • 2012 Clinical and Research Fellow (Hematology and Oncology), III. Department of Medicine, University Hospital of Ulm
  • 2007-2012 Resident Physician (Internal Medicine), III. Department of Medicine, University Hospital of Ulm

Education

  • 2008 Doctoral Thesis ("summa cum laude"), Institute of Pathology, Free University of Berlin
  • 2007 United States Medical Licensing Examination, Step 2
  • 2006 Licensing degree to practice Medicine in Germany

Most relevant publications by Michael Kühn

Kühn MWM, Song E, Feng Z, Sinha A, Chen CW, Deshpande AJ, Cusan M, Rahnamay Farnoud N, Mupo A, Grove C, Koche R, Bradner JE, de Stanchina E, McGeehan G, Vassiliou GS, Hoshii T and Armstrong SA (2016). Targeting Chromatin Regulators Inhibits Leukemogenic Gene Expression in NPM1 Mutant Leukemia. Cancer Discovery, 6, 1166-1181

Kühn MWM and Armstrong SA (2015). Designed to kill: Novel menin-MLL inhibitors target MLL-rearranged leukemia. Cancer Cell, 27, 431-433 

Kühn MWM*, Hadler MJ*, Daigle SR, Koche RP, Krivtsov AV, Olhava EJ, Caligiuri MA, Huang G, Bradner JE, Pollock RM and Armstrong SA (2015). MLL-PTD leukemia cells are sensitive to small molecule DOT1L inhibition. Haematologica, 100, e190-193 *equal contribution

Dolnik A, Engelmann JC, Scharfenberger-Schmeer M, Mauch J, Kelkenberg-Schade S, Haldemann B, Fries T, Krönke J, Kühn MWM, Paschka P, Kayser, Wolf S, Gaidzik VI, Schlenk RF, Rücker FG, Döhner H, Lottaz C, Döhner K and Bullinger L (2013). Commonly altered genomic regions in acute myeloid leukemia are enriched for somatic mutations involved in chromatin-remodeling and splicing. Blood, 120, e83-92

Gröschel S, Schlenk RF, Engelmann J, Rockova V, Teleanu V, Kühn MWM, Eiwen K, Erpelinck C, Havermans M, Lübbert M, Germing U, Schmidt-Wolf IGH, Berna Beverloo H, Schuurhuis GJ, Ossenkoppele GJ, Schlegelberger B, Krauter J, Ganser A, Valk PJM, Löwenberg B, Döhner K, Döhner H* and Delwel R* (2013). Deregulated expression of EVI1 defines a poor prognostic subset of MLL-rearranged acute myeloid leukemias: a study of the German-Austrian AMLSG and Dutch-Belgian HOVON groups. J Clin Oncol, 31, 95-103

Kühn MWM*, Radtke I*, Bullinger L, Goorha S, Cheng J, Edelmann J, Gohlke J, Su X, Paschka P, Pounds S, Krauter J, Ganser A, Quessar A, Ribeiro R, Gaidzik VI, Shurtleff S, Krönke J, Holzmann K, Ma J, Schlenk RF, Rubnitz JE, Döhner K, Döhner H* and Downing JR* (2012). High resolution genomic profiling of adult and pediatric Core-Binding Factor Acute Myeloid Leukemia reveals new recurrent alterations.  Blood, 119, e67-75 *equal contribution

Hummel M, Bentik S, Berger H, Klapper W, Wessendorf S, Barth TFE, Bernd HW, Cogliatti, SB, Dierlamm J, Feller AC, Hansmann ML, Haralambieva E, Harder L, Kühn M, Lenze D, Lichter P, Ignacio MS, Möller P, Müller-Hermelink HK, Ott G, Parwaresch RM, Pott C, Rosenwald A, Rosolowski M, Schwaenen C, Stürzenhofecker B, Szcepanowski M, Trautmann H, Wacker HH, Spang R, Loeffler M, Stein H and Siebert R (2006). A biologic definition of Burkitt’s Lymphoma from transcriptional and genomic profiling. N Engl J Med, 354, 2419-2430

 Research website